Merck logo

Merck

Last updated January 31, 2026
124
Innovation Areas
5,362
Inventors
47
Collaborations

Indazole and bicyclic heterocycle scaffolds: MerckRecent Research Landscape

Viral replication cycles are difficult to interrupt without high cellular toxicity, which is mitigated here through the engineering of specific bicyclic and amido-substituted scaffolds. These structural modifications increase binding affinity to viral polymerases while reducing off-target effects in host cells.

What technical problems is Merck addressing in Indazole and bicyclic heterocycle scaffolds?

Herpesvirus replication and persistence

(15)evidences

Uncontrolled viral proliferation and the lack of effective therapeutic interventions for specific respiratory and herpes infections. Addressing this prevents systemic disease progression and chronic infection cycles.

Viral replication persistence

(4)evidences

Rapid viral mutation leads to treatment failure and drug resistance. Increasing the barrier prevents the emergence of resistant viral strains.

Viral genome integration failure

(3)evidences

Latent reservoirs and ongoing viral integration prevent complete eradication of infection. Addressing these failure modes enables long-term viral suppression and potential cure strategies.